These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 8380487

  • 1. Milacemide therapy for Parkinson's disease.
    Giuffra ME, Sethy VH, Davis TL, Mouradian MM, Chase TN.
    Mov Disord; 1993; 8(1):47-50. PubMed ID: 8380487
    [Abstract] [Full Text] [Related]

  • 2. A trial of dextromethorphan in parkinsonian patients with motor response complications.
    Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natté R, Chase TN.
    Mov Disord; 1998 May; 13(3):414-7. PubMed ID: 9613730
    [Abstract] [Full Text] [Related]

  • 3. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV, Blanchet PJ, de Jong D, Mouradian MM, Chase TN.
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
    Wolters EC, Horstink MW, Roos RA, Jansen EN.
    Adv Neurol; 1993 May; 60():648-52. PubMed ID: 8420204
    [No Abstract] [Full Text] [Related]

  • 7. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 8. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
    Vitek JL, Bakay RA, Freeman A, Evatt M, Green J, McDonald W, Haber M, Barnhart H, Wahlay N, Triche S, Mewes K, Chockkan V, Zhang JY, DeLong MR.
    Ann Neurol; 2003 May; 53(5):558-69. PubMed ID: 12730989
    [Abstract] [Full Text] [Related]

  • 9. Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial.
    Grundmann M, Schimrigk K.
    J Neural Transm Suppl; 1987 May; 25():115-9. PubMed ID: 3323420
    [Abstract] [Full Text] [Related]

  • 10. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
    Metman LV, Sethy VH, Roberts JR, Bravi D, Hoff JI, Mouradian MM, Chase TN.
    Mov Disord; 1994 Sep; 9(5):577-81. PubMed ID: 7990854
    [Abstract] [Full Text] [Related]

  • 11. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H.
    Neurology; 2005 Jan 25; 64(2):216-23. PubMed ID: 15668416
    [Abstract] [Full Text] [Related]

  • 12. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
    Bravi D, Davis TL, Mouradian MM, Chase TN.
    Mov Disord; 1993 Apr 25; 8(2):195-7. PubMed ID: 8097280
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
    Rascol O, Fabre N, Blin O, Poulik J, Sabatini U, Senard JM, Ané M, Montastruc JL, Rascol A.
    Mov Disord; 1994 Jul 25; 9(4):437-40. PubMed ID: 7969211
    [Abstract] [Full Text] [Related]

  • 16. A double-blind evaluation of ciladopa in Parkinson's disease.
    Weiner WJ, Factor SA, Sanchez-Ramos J, Berger J.
    Mov Disord; 1987 Jul 25; 2(3):211-7. PubMed ID: 3332914
    [Abstract] [Full Text] [Related]

  • 17. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
    Marras C, Lang A, Krahn M, Tomlinson G, Naglie G, Parkinson Study Group.
    Mov Disord; 2004 Jan 25; 19(1):22-8. PubMed ID: 14743356
    [Abstract] [Full Text] [Related]

  • 18. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
    García de Yébenes J, Mateo D, Pino MA, Cordero M, Pastor M, Chacón J, Morales B, Sánchez V, Mena MA, Giménez Roldán S.
    Neurologia; 1997 Apr 25; 12(4):145-56. PubMed ID: 9235023
    [Abstract] [Full Text] [Related]

  • 19. Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
    Addy C, Assaid C, Hreniuk D, Stroh M, Xu Y, Herring WJ, Ellenbogen A, Jinnah HA, Kirby L, Leibowitz MT, Stewart RM, Tarsy D, Tetrud J, Stoch SA, Gottesdiener K, Wagner J.
    J Clin Pharmacol; 2009 Jul 25; 49(7):856-64. PubMed ID: 19491335
    [Abstract] [Full Text] [Related]

  • 20. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
    Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW.
    Mov Disord; 2000 May 25; 15(3):485-9. PubMed ID: 10830413
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.